⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 13, 2025

Table 1 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis

Guadalupe Nibeyro Verónica M. Baronetto Agustín Nava María Romina Girotti Laura Prato Gabriel Morón Elmer A. Fernández

View Full Paper

Ask AI

Bookmark

Share

Key Points

Gene fusions may serve as significant prognostic biomarkers in advanced melanoma treatment.
Among 222 patients analyzed, key gene fusions correlated with therapeutic response to immune checkpoint blockade.
Retrospective analysis highlights the importance of molecular profiling in advanced melanoma for treatment strategies.
Identifying gene fusions in patients could enable personalized therapies for advanced melanoma treatment.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Retrospective analysis identifies gene fusions as potential biomarkers in advanced melanoma, suggesting new therapeutic targets.

Abstract

Relevant characteristics of the analyzed cohorts (222 patients)

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nibeyro et al. (2025) studied this question.

synapsesocial.com/papers/68a36a4f0a429f797332ef7e https://doi.org/10.1158/2767-9764.29900432

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S1 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis2025
2Table_S3 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis2025
3Table_S4 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis2025
4Figure 3 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis2025
5Table_S5 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis2025